top of page

ApexOnco's Jacob Plieth shares his take on what to watch for at the 2024 ASH Annual Meeting

blonca9
Dec 7, 2024
1 min read

He talks modalities and targets, and comments on Arcellx, Galapagos, BeiGene, Nurix, Kura, JNJ, Syndax, AbbVie AstraZeneca, CellCentric, and more.

Recent Posts

ASGCT 2025: Physicians and scientists raced to make a bespoke gene editing therapy for an infant who urgently needed one in months - a first hand account, and what this means for drug development

ASGCT 2025: Physicians and scientists raced to make a bespoke gene editing therapy for an infant who urgently needed one in months - a first hand account, and what this means for drug development

Gene therapies expert TJ Cradick previews what to watch for at the 2025 ASGCT Annual Meeting in New Orleans

Gene therapies expert TJ Cradick previews what to watch for at the 2025 ASGCT Annual Meeting in New Orleans

Biotech investor Christoph Broja of EQT Life Sciences discusses biotech in Europe and highlights portfolio companies Tubulis, Agomab Therapeutics, and PanTera

Biotech investor Christoph Broja of EQT Life Sciences discusses biotech in Europe and highlights portfolio companies Tubulis, Agomab Therapeutics, and PanTera

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page